OTHER INFORMATION
−Removed: August 22, 2025 , Eric Yecies , Chief Legal Officer and General Counsel , adopted a Rule 10b5-1 trading arrangement that is intended to
−Removed: satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 200,000 shares of the Company’s common stock, at various
−Removed: limit prices above the current market price of the Company’s common stock as of the plan adoption date, with such transactions
−Removed: to occur during sale periods beginning on or after November 21, 2025 and ending on the earlier of December 31, 2026 or the date on which
−Removed: all shares authorized for sale have been sold in conformance with the terms of the arrangement.
−Removed: described in Part 1, Item 4.
−Removed: Controls and Procedures, we have identified an additional material weakness in our internal control over
−Removed: financial reporting as of September 30, 2025.
−Removed: We have concluded that this material weakness also existed as of December 31, 2024, March
−Removed: 31, 2025 and June 30, 2025.
−Removed: Accordingly, the previous conclusion included in Item 9A of our Form 10-K filed with the Securities and Exchange
−Removed: Commission on March 11, 2025 that our disclosure controls and procedures and internal control over financial reporting were ineffective
−Removed: is hereby updated to include this additional material weakness.
−Removed: Also, the previous conclusions included in Item 4 of our Forms 10-Q filed
−Removed: with the Securities and Exchange Commission on May 6, 2025 and August 5, 2025 that our disclosure controls and procedures was ineffective
−Removed: is hereby updated to also include this additional material weakness.
−Removed: 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer.
−Removed: 13a-14(a) / 15d-14(a) Certification of Chief Financial Officer.
−Removed: 1350 Certification of Chief Executive Officer.
−Removed: 1350 Certification of Chief Financial Officer.
+Added: Resignation & Transition Services Agreement, dated March 16, 2026, between LifeMD, Inc.
+Added: and Marc Benathen.
+Added: Employment Agreement, dated March 16, 2026 between LifeMD, Inc.
+Added: and Atul Kavthekar
+Added: First Renewed Director Agreement, dated October 2, 2025 by and between LifeMD, Inc.
+Added: and Calum MacRae
+Added: Third Amendment to the Director Agreement, dated October 6, 2025, between Dr.
+Added: Joan LaRovere and LifeMD, Inc.
+Added: Credit Agreement between LifeMD, Inc., and Citizens Bank, N.A., dated January 2, 2026
+Added: Guarantee Agreement among LifeMD, Inc., each of the Subsidiary Guarantors party thereto, and Citizens Bank, N.A., dated January 2, 2026
+Added: Pledge and Security Agreement among LifeMD, Inc., each of the Guarantors party thereto, and Citizens Bank, N.A., dated January 2, 2026
+Added: Revolving Loan Note issued by LifeMD, Inc.
+Added: to Citizens Bank, N.A., dated January 2, 2026
+Added: Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer.
+Added: Rule 13a-14(a) / 15d-14(a) Certification of Chief Financial Officer.
+Added: Section 1350 Certification of Chief Executive Officer.
+Added: Section 1350 Certification of Chief Financial Officer.
XBRL Instance Document
12 unchanged sentences
executive officer)
−Removed: Marc Benathen
+Added: Atul Kavthekar
Financial Officer
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.